MARKETS / NASDAQ / AMPH

NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Amphastar Pharmaceuticals, Inc. AMPH

14 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$719.9M

▼ 1.7% YoY

Net income

$98.1M

▼ 38.5% YoY

Free cash flow

$121.2M

▼ 29.7% YoY

In brief

What this company does

It currently manufactures and sells over 25 prescription pharmaceutical products, along with an over-the-counter product, Primatene MIST. As of December 31, 2025, it had 1,976 full-time employees in the United States, China, and France. Its manufacturing facilities are located in Rancho Cucamonga and South El Monte, California; Canton, Massachusetts; Éragny-sur-Epte, France; and Nanjing, China. As of December 31, 2025, it owned or leased a total of 69 buildings at six locations in the United States, France and China, comprising 2.5 million square feet of manufacturing, research and development, distribution, packaging, laboratory, office and warehouse space. For the year ended December 31, 2025, McKesson accounted for 24% of its net revenues. It was incorporated in California under the name Amphastar Pharmaceuticals, Inc. in 1996 and merged into a newly formed Delaware corporation of the same name in 2004.

Written from the business description in Amphastar Pharmaceuticals, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth

USD 719.9M

Revenue, FY2025 · full 14-year series below

Revenue $M Net income $M

FY2025 · Revenue 719.9 · Net income 98.1

Compound annual growth

Revenue

+13.0%

+15.5%

+11.1%

Net income

+2.4%

+133.8%

EPS, diluted

+5.3%

+132.3%

Returned to shareholders

+49.5%

+299.5%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +15.5% a year over five years — but profit grew faster: net income at +133.8%, earnings per share at +132.3%.

The share count fell from 0.05B to 0.05B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

14 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 19.5% · Net 13.6%

ROE

FY2022 · ROE 20.5%

Gross margin49.5%

Operating margin19.5%

Net margin13.6%

Return on assets6.1%

EBITDAUSD 172.1M

Cash & shareholders

USD 69.2M

returned in FY2025 · dividends + net buybacks

Free cash flow $M

FY2025 · FCF 121.2

Net buybacks $M Dividends $M

FY2025 · Dividends — · Net buybacks 69.2

Dividends paid—

Net buybacksUSD 69.2M

Share of profit70.5%

Consecutive raises—

USD 69.2M in buybacks — 71% of the year's profit went back to shareholders.

Total assetsUSD 1.6B

CashUSD 170.2M

Gross debtUSD 619.7M

Net debtUSD 449.5M

Current ratio4.02×

Not available: we don't have the shareholders' equity figure for this period.

The 14-year record

14 fiscal years

Every figure from documents filed with the SEC · USD

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue $B	0.7	0.7	0.6	0.5	0.4	0.3	0.3	0.3	0.2	0.3	0.3	0.2	0.2	0.2
Operating income $B	0.1	0.2	0.2	0.1	0.1	0.0	−0.0	−0.0	−0.0	0.0	−0.0	−0.0	0.0	0.0
EBITDA $B	0.2	0.2	0.2	0.1	0.1	0.0	0.0	−0.0	0.0	0.0	0.0	−0.0	0.0	0.0
Income tax $B	0.0	0.0	0.0	0.0	0.0	0.0	0.0	−0.0	−0.0	0.0	−0.0	−0.0	0.0	0.0
Net income $B	0.1	0.2	0.1	0.1	0.1	0.0	0.0	−0.0	0.0	0.0	−0.0	−0.0	0.0	0.0
Free cash flow $B	0.1	0.2	0.1	0.1	0.1	0.0	0.0	−0.0	0.0	0.0	−0.0	0.0	0.0	−0.0
EPS, diluted $	2.03	3.06	2.60	1.74	1.25	0.03	0.98	−0.12	0.08	0.21	−0.06	−0.25	0.31	0.46
Dividend / sh $	·	·	·	·	·	·	·	·	·	·	·	·	·	·
Payout %	·	·	·	·	·	·	·	·	·	·	·	·	·	·
ROE %	·	·	·	20.5	14.7	0.4	13.7	−1.7	1.1	3.1	−1.0	−4.0	4.9	7.8
Shares out B	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.04	0.04	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 68 reconciliationsAUDITED

Reconciled in 14 of 19 fiscal years. 27 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityPharmaceutical Preparations

Listed onNASDAQ

Incorporated innot stated in the filings

Fiscal year endsDecember 31

Data on record since2012